Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3703-3709

John Wiley & Sons Inc

Access to resources Recommend Favorite

CYP2D6 predicted metabolizer status and safety in adult patients with attention‐deficit hyperactivity disorder participating in a large placebo‐controlled atomoxetine maintenance of response clinical trial

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 10, 2015-10 ,pp. : 1167-1174

John Wiley & Sons Inc

Access to resources Recommend Favorite

Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen

By Fleeman Nigel   Payne Katherine   Newman William G   Howell Sacha J   Boland Angela   Oyee James   Saborido Carlos Martin   Santander Ana Fernández   Dickson Rumona  

Personalized Medicine, Vol. 10, Iss. 6, 2013-08 ,pp. : 601-611

Future Medicine

Access to resources Recommend Favorite

Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID‐Induced Gastropathy

By  

PAIN MEDICINE, Vol. 16, Iss. 5, 2015-05 ,pp. : 866-869

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications

By Albuquerque José   Ribeiro Carolina   Naranjo Maria Eugenia G   Llerena Adrián   Grazina Manuela  

Personalized Medicine, Vol. 10, Iss. 7, 2013-09 ,pp. : 709-718

Future Medicine

Access to resources Recommend Favorite